Edmonton, May 28-30, 2023

Due to the numerous requests from LPs. Micro and Craft growers along with some of the largest cannabis retail stores in the nation, Grow Up has decided to bring our award winning show to Alberta. We will be hosting our 7th Conference and Expo at the Edmonton Convention Centre in beautiful downtown Edmonton.

Researchers Look Into Use of Psilocybin as Cluster Headaches Treatment

Media Partners, Psychedelic News Wire

This post is presented by our media partner Psychedelic News Wire
View the original article here.

Researchers are looking to the nascent psychedelics market to find an alternative treatment for cluster headaches. A growing body of literature has already revealed that psychedelics can be effective at treating a myriad of mental health disorders when paired with psychotherapy. In fact, the majority of the research involving psychedelics, including psilocybin, MDMA and ketamine, has involved their potent mental health benefits.

Yale University researchers have now published the results of the first-ever randomized double-blind, placebo-controlled study on the effects of psilocybin, the main psychoactive agent in magic mushrooms, on cluster headaches. These headaches are a rare neurological condition that affects around 0.1% of the population and cause extremely intense and painful headaches.

Although anecdotal reports from users claim that psilocybin can help relieve the pain from cluster headaches, there is little scientific evidence behind the claims. However, assistant professor of neurology at the Yale School of Medicine and medical director at the Headache Center of Excellence at VA Connecticut Healthcare System and lead researcher Emmanuelle AD Schindler explains that people with cluster headaches have been using psilocybin mushrooms and other psychedelics to self-medicate for decades.

Noting that such patients have reported long-term effects after using limited doses, Schindler wanted to conduct a randomized controlled trial to share this knowledge with the scientific and medical communities. The exploratory study involved 16 adults with cluster headaches randomly receiving either a placebo or 0.143 mg/kg of psilocybin over five days.

The participants filled out headache diaries starting two weeks before they were dosed and then continued for eight weeks following the first dosing session. The researchers found that those who received psilocybin reported a decrease in cluster headache symptoms. However, the reduction in cluster headache symptoms was not statistically significant compared to the placebo.

Schindler said that the “small preliminary study” provided evidence of psilocybin’s therapeutic effectiveness against cluster headaches. She noted that while the 30% drop in the number of weekly headache attacks was not statistically significant, there was clear evidence that some patients responded to the psychedelic while others didn’t. Patients who responded to the treatment saw a 75% reduction in weekly attacks even though the average reduction for the entire study pool was around 30%.

Still, the data gathered in this study could be used to develop larger studies in the future. Schindler said that this study just scratched the surface, and researchers will need larger, more definitive studies with hundreds of patients with adjustable dosing regimens to determine if psilocybin can be an alternative treatment for cluster headaches.

Additional research on other psychedelics is being undertaken by the likes of Seelos Therapeutics Inc. (NASDAQ: SEEL), so the world can look forward to exciting revelations about these substances.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.

This post was originally published by our media partner here.